Focus: Ascend Therapeutics is a specialty pharmaceutical company focused on women's health and related therapeutic areas, with 1,001–5,000 employees headquartered in Herndon, VA. Founded in 2023, it operates as a commercial-stage player with established marketed products.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Ascend Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sole revenue driver generating 100% of company revenue; approaching loss of exclusivity poses existential commercial risk.
Help build intelligence for Ascend Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ascend Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Post-LOE ANDA product with limited commercial potential; represents defensive portfolio play rather than growth driver.
BLA-approved biologic at peak lifecycle stage; offers highest near-term upside potential and differentiation from generic estradiol market.
Pre-launch ANDA formulation; unclear commercial strategy given existing post-LOE ELUXADOLINE in portfolio.
NDA-approved product in growth phase with long exclusivity runway (LOE 2042); critical to offsetting ESTROGEL cliff.
Second pre-launch ANDA formulation; duplication in portfolio signals potential commercial strategy confusion or manufacturing capacity planning.
1 discontinued, 1 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo